drugset / Trial / NCT07231250
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, phase II, prospective study. The main purpose of study is to evaluate the efficacy and safety of Glofitamab plus Polatuzumab vedotin and Zuberitamab in patients with newly diagnosed diffuse large B-cell lymphoma.
Timeline
- Start
- 2026-01-15
- Primary completion
- 2026-09-15
- Completion
- 2028-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |
| Subject | Prednisone | Other / unclassified | — | Oral |
| Subject | Zuberitamab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |